Policy· Brief · November 2, 2026, 5:01 PM ET

BioMarin reports third quarter 2026 financial and operating results

BioMarin said total revenues for the third quarter ended September 30, 2026 rose 32% year-over-year to $1.025 billion, driven by 44% growth in metabolic conditions and 12% growth in skeletal conditions. The company also announced a PDUFA target action date of May 30, 2027 for VOXZOGO in hypochondroplasia and that the EMA validated its submission for VOXZOGO in HCH.

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation